Xdynia LLC spun out from Tau Therapeutics Inc. this year to develop oral small molecule inhibitors of a specific subset of voltage-dependent T type calcium channels that play a prominent role in pain signal transduction. The approach could offer better safety and efficacy for neuropathic pain than available drugs.

According to President Yuri Maricich, up to 60% of patients report no relief from drugs commonly prescribed for neuropathic pain, such as GABA receptor agonists, selective serotonin and norepinephrine reuptake inhibitors (SSNRIs) and opiates.